v3.26.1
Inventory - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Feb. 12, 2026
Dec. 31, 2025
Inventory [Line Items]      
Inventory $ 336,703   $ 196,625
Work in process 120,844   90,498
Finished goods [1] 144,893   $ 37,740
Step-up Adjustment | Avadel Pharmaceuticals Plc      
Inventory [Line Items]      
Inventory   $ 121,600  
Work in process   19,100  
Finished goods   $ 102,500  
Step-up Adjustment | Avadel Pharmaceuticals Plc | Cost of goods manufactured and sold      
Inventory [Line Items]      
Inventory amortization $ 12,700    
[1] At March 31, 2026 and December 31, 2025, the Company had $26.2 million and $31.7 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

In connection with the Avadel Acquisition, the Company recorded a fair value step-up adjustment to inventory of $121.6 million, consisting of approximately $19.1 million and $102.5 million in work in process and finished goods, respectively. The inventory step-up is being amortized when inventory is sold to customers, substantially all of which is expected to be within a year of the Closing Date. During the three months ended March 31, 2026, the Company amortized $12.7 million in inventory step-up within “Cost of goods manufactured and sold” in the accompanying condensed consolidated statement of operations and comprehensive (loss) income.